Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

Barclays analyst Glen Santangelo has maintained an Overweight rating on Xeris Biopharma Holdings (NASDAQ: XERS) and raised the price target from $12 to $14. This adjustment reflects a positive outlook for the company's performance in the market.